Market research
KOD Kodiak Sciences Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 69
- Dividend yield
- Not available
- Beta
- 2.21
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US50015M1099
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 69
- Dividend yield
- Not available
- Beta
- 2.21
About
About Kodiak Sciences Inc
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company's preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), a bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the KOD discussion.
5 years, 4 months ago
Kodiak Sciences Inc is currently in a long term downtrend where the price is trading 19.2% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Kodiak Sciences Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 198.3% to $-47M since the same quarter in the previous year.
Finally, its free cash flow fell by 181.0% to $-32M since the same quarter in the previous year.
Based on the above factors, Kodiak Sciences Inc gets an overall score of 1/5.